Day One Biopharmaceuticals, Inc. (DAWN)

17.17 -0.40 (-2.28%) At close: 04:00PM EDT

Day One Biopharmaceuticals, Inc.

2000 Sierra Point Parkway
Suite 501
Brisbane, CA 94005
United States
650 484 0899
https://dayonebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 155

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jeremy Bender M.B.A., Ph.D.	CEO, President & Director	1.05M	N/A	1971
Dr. Samuel C. Blackman M.D., Ph.D.	Co-Founder and Head of R&D	740.5k	N/A	1969
Mr. Charles N. York II, M.B.A.	COO, CFO & Secretary	760k	N/A	1977
Mr. Adam Dubow	General Counsel and Chief Compliance Officer	608.2k	N/A	1967
Dr. Mike Preigh Ph.D.	Chief of Technology Operations	N/A	N/A	N/A
Ms. Jaa Roberson	Chief People Officer	N/A	N/A	N/A
Dr. Davy Chiodin Ph.D., Pharm.D.	Chief Development Officer	N/A	N/A	N/A
Ms. Lauren Merendino M.B.A.	Chief Commercial Officer	N/A	N/A	1976
Dr. Elly Barry M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Corporate governance

Day One Biopharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.